{"id":2867,"date":"2025-01-21T19:12:32","date_gmt":"2025-01-21T19:12:32","guid":{"rendered":"https:\/\/ukfinancepulse.com\/?p=2867"},"modified":"2025-01-21T20:02:22","modified_gmt":"2025-01-21T20:02:22","slug":"fda-approves-jjs-spravato-as-standalone-depression-treatment","status":"publish","type":"post","link":"https:\/\/ukfinancepulse.com\/?p=2867","title":{"rendered":"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment"},"content":{"rendered":"\n<p>The Food and Drug Administration (FDA) has approved Johnson &amp; Johnson\u2019s Spravato as the first standalone therapy for adults with treatment-resistant depression. This groundbreaking approval opens new doors for millions of patients who struggle with symptoms that fail to respond to traditional antidepressants.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A New Option for Treatment-Resistant Depression<\/strong><\/h3>\n\n\n\n<p>Spravato, a nasal spray derived from ketamine, has been used in combination with oral antidepressants since its 2019 launch. This latest approval marks a significant milestone, allowing it to be prescribed on its own. Dr. Gregory Mattingly, president of the Midwest Research Group, emphasized, \u201cFor the first time ever, we now have an option that gives patients freedom.\u201d<\/p>\n\n\n\n<p>This freedom is particularly crucial for the one-third of U.S. adults with major depression who don\u2019t respond to traditional therapies. Symptoms such as persistent sadness, low energy, and suicidal thoughts often remain unresolved, creating a dire need for innovative treatments.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Proven Efficacy and Rapid Relief<\/strong><\/h3>\n\n\n\n<p>The FDA\u2019s decision was based on a phase four trial showing Spravato\u2019s ability to improve depressive symptoms within 24 hours, with effects lasting up to a month. Johnson &amp; Johnson\u2019s global neuroscience head, Bill Martin, noted, \u201cThis demonstrates not only rapid symptom relief but also durable symptom relief.\u201d<\/p>\n\n\n\n<p>Unlike traditional oral antidepressants, which can take weeks to show results, Spravato offers almost immediate improvements. Mattingly highlighted, \u201cQuite often with the same day, the very next day, people can already start to feel they\u2019re somewhat better.\u201d<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Safety Measures and Restricted Access<\/strong><\/h3>\n\n\n\n<p>Given its ketamine roots, Spravato carries a risk of sedation, dissociation, and potential misuse. To mitigate these risks, it\u2019s only available through certified healthcare settings where patients are monitored for two hours post-administration. This ensures the drug is administered safely and under strict supervision.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Transformative Growth and Future Potential<\/strong><\/h3>\n\n\n\n<p>Spravato\u2019s trajectory has transformed over the years. Initially, its launch was slow, complicated by the pandemic and the need for in-person monitoring. However, increased awareness and marketing efforts have bolstered its acceptance.<\/p>\n\n\n\n<p>In the first nine months of 2024, Spravato generated $780 million in sales, and Johnson &amp; Johnson expects annual revenues to grow between $1 billion and $5 billion. This growth comes at a critical time as the company prepares for patent expirations on other major drugs.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A Hopeful Step for Mental Health<\/strong><\/h3>\n\n\n\n<p>The approval of Spravato as a standalone therapy signifies a major leap in mental health treatment. By offering rapid and effective relief, it provides a new lifeline for patients who have long struggled with limited options. As Martin aptly put it, \u201cThis approval provides an avenue for caregivers and their patients to optimize and personalize the treatment paradigm for each individual.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Food and Drug Administration (FDA) has approved Johnson &amp; Johnson\u2019s Spravato as the first standalone therapy for adults with treatment-resistant depression. This groundbreaking approval opens new doors for millions of patients who struggle with symptoms that fail to respond to traditional antidepressants. A New Option for Treatment-Resistant Depression Spravato, a nasal spray derived from [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":2852,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":{"0":"post-2867","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment - UK Finance Pulse<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ukfinancepulse.com\/?p=2867\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment - UK Finance Pulse\" \/>\n<meta property=\"og:description\" content=\"The Food and Drug Administration (FDA) has approved Johnson &amp; Johnson\u2019s Spravato as the first standalone therapy for adults with treatment-resistant depression. This groundbreaking approval opens new doors for millions of patients who struggle with symptoms that fail to respond to traditional antidepressants. A New Option for Treatment-Resistant Depression Spravato, a nasal spray derived from [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ukfinancepulse.com\/?p=2867\" \/>\n<meta property=\"og:site_name\" content=\"UK Finance Pulse\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-21T19:12:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-21T20:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ukfinancepulse.com\/wp-content\/uploads\/2025\/01\/business-3.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1480\" \/>\n\t<meta property=\"og:image:height\" content=\"833\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Nathaniel Hayes\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867\"},\"author\":{\"name\":\"Nathaniel Hayes\",\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/#\\\/schema\\\/person\\\/eceb8292e84c982eda13144d20aeae39\"},\"headline\":\"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment\",\"datePublished\":\"2025-01-21T19:12:32+00:00\",\"dateModified\":\"2025-01-21T20:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867\"},\"wordCount\":450,\"image\":{\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ukfinancepulse.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/business-3.webp\",\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867\",\"url\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867\",\"name\":\"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment - UK Finance Pulse\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ukfinancepulse.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/business-3.webp\",\"datePublished\":\"2025-01-21T19:12:32+00:00\",\"dateModified\":\"2025-01-21T20:02:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/#\\\/schema\\\/person\\\/eceb8292e84c982eda13144d20aeae39\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867#primaryimage\",\"url\":\"https:\\\/\\\/ukfinancepulse.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/business-3.webp\",\"contentUrl\":\"https:\\\/\\\/ukfinancepulse.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/business-3.webp\",\"width\":1480,\"height\":833},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/?p=2867#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ukfinancepulse.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/#website\",\"url\":\"https:\\\/\\\/ukfinancepulse.com\\\/\",\"name\":\"UK Finance Pulse\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ukfinancepulse.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ukfinancepulse.com\\\/#\\\/schema\\\/person\\\/eceb8292e84c982eda13144d20aeae39\",\"name\":\"Nathaniel Hayes\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/050e48c61c8a2844c1b55d3d5f87651302ae064c362007dc854374316dce1043?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/050e48c61c8a2844c1b55d3d5f87651302ae064c362007dc854374316dce1043?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/050e48c61c8a2844c1b55d3d5f87651302ae064c362007dc854374316dce1043?s=96&d=mm&r=g\",\"caption\":\"Nathaniel Hayes\"},\"url\":\"https:\\\/\\\/ukfinancepulse.com\\\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment - UK Finance Pulse","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ukfinancepulse.com\/?p=2867","og_locale":"en_US","og_type":"article","og_title":"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment - UK Finance Pulse","og_description":"The Food and Drug Administration (FDA) has approved Johnson &amp; Johnson\u2019s Spravato as the first standalone therapy for adults with treatment-resistant depression. This groundbreaking approval opens new doors for millions of patients who struggle with symptoms that fail to respond to traditional antidepressants. A New Option for Treatment-Resistant Depression Spravato, a nasal spray derived from [&hellip;]","og_url":"https:\/\/ukfinancepulse.com\/?p=2867","og_site_name":"UK Finance Pulse","article_published_time":"2025-01-21T19:12:32+00:00","article_modified_time":"2025-01-21T20:02:22+00:00","og_image":[{"width":1480,"height":833,"url":"https:\/\/ukfinancepulse.com\/wp-content\/uploads\/2025\/01\/business-3.webp","type":"image\/webp"}],"author":"Nathaniel Hayes","twitter_card":"summary_large_image","twitter_misc":{"Written by":false,"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ukfinancepulse.com\/?p=2867#article","isPartOf":{"@id":"https:\/\/ukfinancepulse.com\/?p=2867"},"author":{"name":"Nathaniel Hayes","@id":"https:\/\/ukfinancepulse.com\/#\/schema\/person\/eceb8292e84c982eda13144d20aeae39"},"headline":"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment","datePublished":"2025-01-21T19:12:32+00:00","dateModified":"2025-01-21T20:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/ukfinancepulse.com\/?p=2867"},"wordCount":450,"image":{"@id":"https:\/\/ukfinancepulse.com\/?p=2867#primaryimage"},"thumbnailUrl":"https:\/\/ukfinancepulse.com\/wp-content\/uploads\/2025\/01\/business-3.webp","articleSection":["Business"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ukfinancepulse.com\/?p=2867","url":"https:\/\/ukfinancepulse.com\/?p=2867","name":"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment - UK Finance Pulse","isPartOf":{"@id":"https:\/\/ukfinancepulse.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ukfinancepulse.com\/?p=2867#primaryimage"},"image":{"@id":"https:\/\/ukfinancepulse.com\/?p=2867#primaryimage"},"thumbnailUrl":"https:\/\/ukfinancepulse.com\/wp-content\/uploads\/2025\/01\/business-3.webp","datePublished":"2025-01-21T19:12:32+00:00","dateModified":"2025-01-21T20:02:22+00:00","author":{"@id":"https:\/\/ukfinancepulse.com\/#\/schema\/person\/eceb8292e84c982eda13144d20aeae39"},"breadcrumb":{"@id":"https:\/\/ukfinancepulse.com\/?p=2867#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ukfinancepulse.com\/?p=2867"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ukfinancepulse.com\/?p=2867#primaryimage","url":"https:\/\/ukfinancepulse.com\/wp-content\/uploads\/2025\/01\/business-3.webp","contentUrl":"https:\/\/ukfinancepulse.com\/wp-content\/uploads\/2025\/01\/business-3.webp","width":1480,"height":833},{"@type":"BreadcrumbList","@id":"https:\/\/ukfinancepulse.com\/?p=2867#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ukfinancepulse.com\/"},{"@type":"ListItem","position":2,"name":"FDA Approves J&amp;J\u2019s Spravato as Standalone Depression Treatment"}]},{"@type":"WebSite","@id":"https:\/\/ukfinancepulse.com\/#website","url":"https:\/\/ukfinancepulse.com\/","name":"UK Finance Pulse","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ukfinancepulse.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ukfinancepulse.com\/#\/schema\/person\/eceb8292e84c982eda13144d20aeae39","name":"Nathaniel Hayes","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/050e48c61c8a2844c1b55d3d5f87651302ae064c362007dc854374316dce1043?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/050e48c61c8a2844c1b55d3d5f87651302ae064c362007dc854374316dce1043?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/050e48c61c8a2844c1b55d3d5f87651302ae064c362007dc854374316dce1043?s=96&d=mm&r=g","caption":"Nathaniel Hayes"},"url":"https:\/\/ukfinancepulse.com\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=\/wp\/v2\/posts\/2867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2867"}],"version-history":[{"count":1,"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=\/wp\/v2\/posts\/2867\/revisions"}],"predecessor-version":[{"id":2873,"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=\/wp\/v2\/posts\/2867\/revisions\/2873"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=\/wp\/v2\/media\/2852"}],"wp:attachment":[{"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ukfinancepulse.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}